Jan 26 PRNewswireFirstCall Novavax Inc

You'll see them also. This article is also featured on Voice of the Islander Fans. DUBLIN, Ireland(Business Wire)Research and Markets( http://) hasannounced the addition of the "Turkey Banking Sector Forecast to 2012" report totheir offering. When all the major economies of the world are reeling under the pressure offinancial crisis, the banking industry in Turkey continued to grow in 2008 andforeign participation also increased. The ratio of deposits and loans to GDP,and the ratio of loans to deposits are important indicators of financial depthand intermediation level of the banking industry, and these indicators shonebright. On domestic front, retail consumers will continue todrive the credit disbursal and interest-based income of banks in coming years. Despite high losses incurred by prominent international banks due to the globalturmoil, the profitability of the Turkish banking industry improved in 2007 andthe return on assets as well as on equity of the industry increased. ConsideringTurkey's population, the size of its economy, economic power, per capita depositand per capita loan figures, the banking industry is still in developmentprocess and has further growth potential.

Turkey's banking industry is financially strong to cope with mild short-termstress. The industry has undergone a process of consolidation as a result ofbank failures in 2000-01, while banking regulation and supervision have beenimproved greatly. The industry will continue to witness growth despite theglobal financial crisis and banks will continue their expansion plans in comingyears. "Turkey Banking Sector Forecast to 2012" provides extensive research andrational analysis on the Turkish banking industry.

This report has been made tohelp clients in analyzing the opportunities, challenges and drivers critical tothe growth of banking industry in Turkey. It gives a brief account of the Political, Economic, Social and Technologicalenvironment of the country with respect to its banking industry to betterevaluate the forces influencing it. Coupled with this, the analytical reportprovides details on various parameters like asset size, income level etc. of thebanking industry to give a rational overview on its future direction. Companies Mentioned: GarantiBank Yapi Kredi Akbank Is Bankasi Turkiye Vakiflar Bankasi T.A.O.For more information visit http:// and MarketsLaura Wood, Senior ManagerFax from USA: 646-607-1907Fax from rest of the world: Copyright Business Wire 2009. Novavax Announces Operational Status of Its Vaccine Pilot Plant and CommercialLaunch FacilityRockville Facility will manufacture Clinical Lots and is Equipped to ProduceFuture Commercial Products using its Innovative Disposable ManufacturingSystem for its Virus-Like Particle (VLP) Vaccine TechnologyROCKVILLE, Md., Jan 26 /PRNewswire-FirstCall/ Novavax, Inc. (Nasdaq:NVAX) announced today that all equipment in its new Good ManufacturingPractice ("GMP") Pilot Plant to manufacture pandemic and seasonal influenzavaccine clinical supplies and commercial batches at a 1,000 liter scale areinstalled and ready for operations supporting scale-up and validation.The project was initiated in December 2007.The facility demolition,construction and initial qualification were completed in 120 days and wereannounced with a ribbon cutting in May 2008.The original design by JacobsEngineering (Conshohocken, PA), which included multiple Wave bioreactors forproduction of VLPs, has been modified to include stirred reactors based on thepotential for enhanced production yield.The stirred reactors, which utilizedisposable liners in keeping with the desire to maintain a disposablemanufacturing process, were received September 2008 and are now installed inthe facility.The facility is expected to be capable of producing 2-3 million doses ofmonovalent pandemic influenza vaccine per week at 15 mcg HA/dose (50 - 75 Mdoses in 6 months) once scale-up and validation are complete.Likewise, thefacility can support up to 20 - 25 million doses of trivalent influenzavaccine in six months.The facility is GMP compliant and includes a total of10,000 square feet of production and support space.The facility alsoincludes media and reagent preparation space and equipment for production ofvaccine for clinical trials.Large-scale commercial production, media,reagent and filling of bulk vaccines are planned to be outsourced.The total cost of the project, including demolition, construction, andinstallation of laboratory and production equipment, was approximately $5million.The facility had existing mechanical systems in place(pharmaceutical air and water system) that were not included in the projectcost.This facility serves as a prototype for regional 'in-border' pandemicinfluenza production facilities which are offered to governments who want toensure a rapid supply of pandemic influenza vaccine for their country.Tokeep the facility in a state of operational readiness for pandemic influenzaproduction, seasonal influenza vaccine and other future VLP-based vaccinesfrom Novavax may also be prepared.Additional information including anarticle published in BioPharm International (January 2009) and photographs ofthe facility are available on Novavax's website: http:// underthe manufacturing section.The next steps for the facility include scale-up and validation of theprocess at full 1000L commercial scale, production of consistency lots forinfluenza vaccines, and regulatory review of the manufacturing and validationdata once phase 3 clinical results are complete."The facility demonstrates the low capital cost of manufacturing withsingle use systems," said Jim Robinson, Vice President of Technical andQuality Operations."Other manufacturers are spending hundreds of millions ofdollars to build similar capacity.The high cost of typical vaccinemanufacturing makes it difficult for a country to afford self-reliance forpandemic flu vaccine supply.Novavax can make a difference in protectingpopulations through our innovative manufacturing approach and ourcollaboration with GE Healthcare.""This $5 million investment is the last significant capital expenditurerequired for manufacturing until after product launch," said Rahul Singhvi,CEO."It supports our development pipeline and initial commercial needs.Thefacility can be expanded with additional bioreactors for additional capacityif needed."About NovavaxNovavax, Inc.

is a clinical stage biotechnology company, creating novelvaccines to address a broad range of infectious diseases worldwide usingadvanced proprietary virus-like particle (VLP) technology.The Companyproduces these VLP based, potent, recombinant vaccines utilizing new, andefficient manufacturing approaches.Additional information about Novavax isavailable at and in the Company's various filings with theSecurities and Exchange Commission.Forward Looking StatementStatements herein relating to future development results and performance,conditions or strategies and other matters, including expectations regardingproduct and clinical developments are forward-looking statements within themeaning of the Private Securities Litigation Reform Act. Novavax cautions thatthese forward-looking statements are subject to numerous assumptions, risksand uncertainties, which change over time. Further information on the factors and risks thatcould affect Novavax's business, financial conditions and results ofoperations, is contained in Novavax's filings with the U.S. Securities andExchange Commission, which are available at http:// These forward-looking statements speak only as of the date of this press release, andNovavax assumes no duty to update forward-looking statements.Available Topic Expert(s): For information on the listed expert(s), clickappropriate link.James Robinson, PE , Inc.Tricia J Richardson of Novavax, Inc., 1-240-268-2031. ) England - BelarusWednesday 14 October 2009, Wembley StadiumWorld Cup 2010 Qualifier Kick-Off: 20:00 EnglandEngland will be without the services of Wayne Rooney as they welcome Belarus to Wembley for the final match of Group Six qualifications for the 2010 World Cup in South Africa.Fabio Capello, who boasted a perfect record for England in World Cup qualifiers prior to Saturdays 1-0 defeat to Ukraine, will likely choose between Steven Gerrard, Gabriel Agbonlahor, Peter Crouch and Carlton Cole to partner Emile Heskey in attack for this upcomingEngland vs Belarus fixture.Gerrard, who has been nursing a groin injury, may be odd man out as England have already booked their place in next summers finals. The Liverpool midfielder lasted only 45 minutes against Ukraine.Robert Green will be a spectator after his red card against Ukraine reduced England to 10 men after only 15 minutes. David James replaced the West Ham keeper and put in an admirable display in the loss, and will likely feature again for England.Rio Ferdinand has returned from injury but has yet to really leave his stamp on the gameat least not in a positive way.